论文部分内容阅读
目的:系统评价非那雄胺治疗良性前列腺增生(BPH)并发血尿的有效性。方法:电子检索MED-LINE(1966年12月至2009年4月)、EMBASE(1974年12月至2009年4月)、Cochrane图书馆(2009年第1期)和中国期刊全文数据库(1994年12月至2009年4月)、中文科技期刊全文数据库(1989年12月至2009年4月)、中国生物医学文献数据库(1978年12月至2009年4月),并手工检索相关杂志。纳入相关的随机对照试验(RCT),由至少两位系统评价员独立进行文献筛查和质量评价,分歧通过讨论解决,采用RevMan5.0软件进行Meta分析。结果:Meta分析结果显示:12个月后与安慰剂组比较,非那雄胺组的血尿发生率明显降低(OR0.11,95%CI:0.06～0.21),有显著性差异(P<0.05)。结论:非那雄胺对BPH并发血尿有良好的治疗及预防作用。建议大样本、多中心、设计良好的RCT,提供更佳循证医学依据。
Objective: To systematically evaluate the efficacy of finasteride in the treatment of hematuria associated with benign prostatic hyperplasia (BPH). METHODS: MEDLINE (December 1966 to April 2009), EMBASE (December 1974 to April 2009), Cochrane Library (January 2009) and Chinese Journal Full-text Database (1994) were searched electronically December to April 2009), the full-text database of Chinese scientific journals (December 1989 to April 2009), the China Biomedical Literature Database (December 1978 to April 2009) and hand-searching of relevant magazines. Included in the relevant RCTs, at least two systematic reviewers independently conducted literature screening and quality evaluation, disagreements were resolved by discussion, and Meta-analysis was performed using RevMan 5.0 software. Results: Meta analysis showed that the incidence of hematuria in finasteride group was significantly lower than that in placebo group after 12 months (OR0.11,95% CI: 0.06-0.21), with significant difference (P <0.05 ). Conclusion: Finasteride has a good therapeutic and preventive effect on BPH complicated with hematuria. Recommendations Large samples, multicenter, well-designed RCTs provide a better evidence-based medical basis.